PAZ Pharma Zen

[percy]

Percy I think you might need to top up a few to get us up to 21cents!

I am more than happy at 20 cents.
21 cents will come,then 25 cents ,and I would guess 30 cents around next year's agm.
Then ?????..my guess is more fun.
No news until September's 1st half result.

[whatsup]

There you go a trade at .21 , are the half yearly numbers out early ?

[RupertBear]

There you go a trade at .21 , are the half yearly numbers out early ?

Wahooooo

[percy]

There you go a trade at .21 , are the half yearly numbers out early ?

No.They should be out in September.
Like RB.Wahooooo.
Thought we were "in limbo" at 20 cents.
Happily wrong again.!

[percy]

We all know that liquidity on unlisted is, and can be a very big issue.
We are now seeing that with PAZ,with a lot of shares offered for sale at 20 cents and above.
Buyers have gone on holiday,with the highest buyer at 14 cents.
What has surprised me is the huge number of shares traded at increasing prices over the past 8 months or so.

[Baa_Baa]

Our ramping must be working

11.12.18 "a few months" ago, seems to have worked a treat, especially recent months with the large seller entertaining new buyers at ever higher prices.

[Lola]

11.12.18 "a few months" ago, seems to have worked a treat, especially recent months with the large seller entertaining new buyers at ever higher prices.

hi woolly one
must be the same pro as fed quacking ducks
Wanting PLX

[Joshuatree]

I need an interpreter for Lola

[Lola]

I need an interpreter for Lola

Sorry Jossie but this girl is autistic. Youll have to talk with the Woolly one

[Arthur]

August 1, 2019
Press Release
PharmaZen pre-tax profit jumps 134% to $1.83 million for the half year.
It has taken biotechnology company PharmaZen Limited just six months to surpass its record full year result of 2018.
Sales for the six months to June 30, jumped 50% to $8.312m from the prior year figure of $5.561m and pre-tax profit increased 134% from $785,000 to $1.839m.
The full year 2018 result was a pre-tax profit of $1.792m on turnover of $12.573m.
Based in Christchurch, PharmaZen is an innovative developer, manufacturer and marketer of science-based, natural, nutritional ingredients. Shares in PharmaZen are traded through the Unlisted securities trading platform.
Managing Director Craig McIntosh described the result as being exceptionally pleasing.
“Our 2018 result gave shareholders a glimpse of the business’s potential as our long-term investments started to come on stream. The first six months of 2019 reinforces that performance but also starts to add some magnitude to the potential,” he said.
The full year pre-tax profit for the company was forecast at the company’s AGM to be $2.8m on turnover of $14.5m. McIntosh advised that the board of directors has since signed off an upgraded full year forecast of $3.9m pre-tax profit on $16.5m turnover.
“While we to tend to err on the conservative side, the first six months have been well beyond expectations and it is an absolute credit to the staff and management that they have been able to accommodate such an increase.
“Not only has the company benefited from the strong demand, but it has also had a six-month run without any major disruption with capital projects.”
McIntosh believes this is a combination of timing and experience gained from prior projects; however, is quick to emphasise it doesn’t mean things are slowing down in terms of expansion.
“We have the resin column plant all onsite and ready for installation and the building fitout for our finished product range is largely complete. The equipment for the facility will arrive over the next two months and will enable us to produce a complete range of finished products – soft gel oils through to hard shell capsules.”
PharmaZen has also commenced design work for a 1,200 sqm building on their adjacent Nuttall Drive properties.
McIntosh was reluctant to divulge what the building would be housing but confirmed it would complete the fullsite development.
“There are a couple of gaps left in our technology portfolio that we would like to have on the current site and we are looking to move our research and development department into a purpose-built facility. This will reinforce the site as our centre of excellence while at the same time allowing expansion in other geographically advantageous locations,” he said.
The management team has also been strengthened with the appointment of Katherine Reardon to head Sales and Marketing for consumer brands.
“Katherine comes to us with extensive industry background and is the ideal person to assist us launch our ranges domestically and internationally.”
The company is in the final stages of strengthening its product development function with further appointments.
Further information : Craig McIntosh, P : (03) 337-4852 | 021-372-069